Tirofiban-induced coronary thrombolysis

Journal of Invasive Cardiology

Volumn 11, Issue 3, 1999, Pages 138-140

  Jayasundera, Timothy G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TIROFIBAN; TYROSINE;

ARTICLE; CASE REPORT; CORONARY ARTERY OBSTRUCTION; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY STENOSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; TYROSINE;

EID: 0242641349     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.